David P. Meeker - 14 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker
Issuer symbol
RYTM
Transactions as of
14 Feb 2025
Net transactions value
-$566,249
Form type
4
Filing time
19 Feb 2025, 21:48:18 UTC
Previous filing
04 Feb 2025
Next filing
05 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +21,250 +11% 211,177 16 Feb 2025 Direct F1
transaction RYTM Common Stock Sale $566,249 -9,896 -4.7% $57.22 201,281 19 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +133,350 $0.000000 133,350 14 Feb 2025 Common Stock 133,350 Direct F1, F3
transaction RYTM Stock Options (Right to Buy) Award $0 +200,000 $0.000000 200,000 14 Feb 2025 Common Stock 200,000 $56.69 Direct F4
transaction RYTM Restricted Stock Units Options Exercise $0 -21,250 -25% $0.000000 63,750 16 Feb 2025 Common Stock 21,250 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
F4 The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F5 The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.